Telomir says Ohio State research shows Telomir-Zn inhibits growth in human, canine osteosarcoma cell lines

• Telomir Pharmaceuticals disclosed in-vitro research with Ohio State showing Telomir-Zn inhibited growth in human and canine osteosarcoma models.
• Results were presented in the announcement, not slated for a future conference readout.
• Management signaled a potential in vivo canine osteosarcoma study, positioning it as a translational path toward human osteosarcoma development.
• Primary near-term focus remains its triple-negative breast cancer program, moving toward site initiation for Phase 1/2 enrollment under an FDA-cleared IND.
• Update broadens optionality for Telomir-Zn, potentially supporting multiple oncology indications while the lead TNBC program advances.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Telomir Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609140800PRIMZONEFULLFEED9824981) on September 14, 2026, and is solely responsible for the information contained therein.